Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359176 | 1.00 | MEN1 (0.41) | MEN1KMT2AATMCYP2C9CYP2C19 | |
| SCHEMBL6356994 | 0.93 | THRA (0.39) | MEN1KMT2ASMN1; SMN2CTSKALDH1A1 | |
| SCHEMBL6356523 | 0.93 | THRA (0.39) | MEN1KMT2ASMN1; SMN2CTSKALDH1A1 | |
| SCHEMBL7657951 | 0.92 | ALDH1A1 (0.38) | MEN1KMT2ASMN1; SMN2CTSKALDH1A1 | |
| SCHEMBL6362116 | 0.92 | ALDH1A1 (0.38) | MEN1KMT2ASMN1; SMN2CTSKALDH1A1 | |
| SCHEMBL6359207 | 0.89 | ALDH1A1 (0.39) | MEN1KMT2ASMN1; SMN2CTSKALDH1A1 | |
| SCHEMBL6362871 | 0.89 | ALDH1A1 (0.39) | MEN1KMT2ASMN1; SMN2CTSKALDH1A1 | |
| SCHEMBL6355462 | 0.85 | ALDH1A1 (0.43) | MEN1KMT2AATMMAPK1CTSK | |
| SCHEMBL6353468 | 0.85 | ALDH1A1 (0.43) | MEN1KMT2AATMMAPK1CTSK | |
| SCHEMBL6357946 | 0.85 | ALDH1A1 (0.38) | MEN1KMT2ASMN1; SMN2CTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | ALLOS THERAPEUTICS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6894185-B2 | Substituted chiral allosteric hemoglobin modifiers | Allós Therapeutics, Inc. (US) | 2005-05-17 | — | — | US | disclosed |
| US-6486342-B1 | Substituted chiral allosteric hemoglobin modifiers | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | MEN1 4867/4885KMT2A 1425/4885ATM 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.